Use access key #2 to skip to page content.
$8.65 -0.08 (-0.92%)
10/6/2008 4:00 PM

Obagi Medical Products, Inc. (OMPI)

CAPS Rating:
*****

A pharmaceutical company focused on the aesthetic and skin health markets. The Company develops and commercializes prescription-based, topical skin health systems.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating OMPI

Add Stock to Watchlist

What the Community Thinks

Total Members

277 Outperforms
4 Underperforms
 

All-Stars

36 Outperforms
1 Underperforms
 

Wall Street

6 Outperforms
0 Underperforms
 

Members bullish on OMPI are also bullish on:

Members bearish on OMPI are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295), IPO in 2006 (165)
Suggest a tag

Obagi Medical Products, Inc. At A Glance

Current Price: $8.65
Last Trade Time: 10/6/2008 4:00 PM
Open: $8.56
Previous Close: $8.73
Daily Range: $7.79 - $8.73
52-Week Range: $6.80 - $25.60
Volume: 299,363
Market Cap: $197.73M
P/E Ratio: 12.30
Compare Our Special Broker Offers!

Stock Trends

OMPI VS S&P 500 (SPY)

OMPI 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for OMPI

More Headlines...

Top Bull Pitch

Recs

7

Obagi Medical Products, Inc. (OMPI)

Avatar ajblank (< 20) Submitted: 5/14/08 8:18 AM

Are you kidding me???? NO DEBT and accumulating cash each quarter, this is the balance sheet that ALL companies which they had. Even with mediocre earnings which they sand bagged for next quarter (huge upside). This is a possible takeover target for a company such as Allergen. Regardless of a possib...More

Replies: 2 | Reply | Permalink

Top Bear Pitch

Recs

1

Obagi Medical Products, Inc. (OMPI)

Avatar chk999 (99.99) Submitted: 7/23/07 12:25 PM

Purely a momentum play. This is very down


on a day the market is climbing.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 36 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

0

 (OMPI)

Avatar osusports10 (< 20) Submitted: 8/02/08 5:34 PM : Outperform Start Price: $9.82 OMPI Score: 5.03

No Debt! Key to growth in a company and undervalued. Will double in the next year after recent drop!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OMPI)

Avatar MJKpayday (96.28) Submitted: 7/12/08 10:31 PM : Outperform Start Price: $9.53 OMPI Score: 13.05

OMPI

Business
Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne and soft tissue deficits, such as fine lines and wrinkles.

Financials
-15-25% top line growth with no end in site
- High profit margins
- Negligible debt
- PE:13
- PB:4

What it's missing:
- Tenured management
- Product diversity (70% of revenue comes from one line)
- An established moat
- FDA assured safe products (FDA cannot assure users that hydroquinone is not a carcinogen)
- An extreme undervaluation

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OMPI)

Avatar DavidBear (24.57) Submitted: 7/09/08 12:10 PM : Outperform Start Price: $8.93 OMPI Score: 14.52

With a EV to FCF ratio of about 10, it is hard not to like a stock that has been growing by 20%+ per year. If we are entering a recession, then med-biotech is a good place to be, and dermatology for the old and rich will not go away.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OMPI)

Avatar PebbledShore (< 20) Submitted: 7/02/08 10:22 PM : Outperform Start Price: $8.07 OMPI Score: 24.80

What the heck? I need points!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OMPI)

Avatar hansthered0 (< 20) Submitted: 6/15/08 1:38 PM : Outperform Start Price: $8.82 OMPI Score: 20.21

O'snappessy Growth

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 5 of 36 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackStanfordRes 45.12 09/25/08 Outperform NS $10.16-14.86%-12.37%-2.49
TrackRothCapital < 20 05/20/08 Outperform NS $7.85+10.19%-26.54%+36.73
TrackSusquehanna < 20 10/22/07 Outperform NS $20.49-57.78%-29.65%-28.13
TrackRWBaird 95.01 05/08/07 Outperform NS $15.82-45.32%-30.46%-14.87
TrackJPMorgan < 20 01/24/07 Outperform NS $9.25-6.49%-26.36%+19.87
TrackTWeisel < 20 01/24/07 Outperform NS $9.25-6.49%-26.36%+19.87

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners